Rockwell Medical Inc (Rockwell) specializes in the development, manufacturing, commercialization, and distribution of hemodialysis products. The company’s core offerings are integral to the dialysis treatment process, which involves the use of concentrated solutions to create dialysate. Dialysate, an essential component in hemodialysis, facilitates the exchange of bicarbonate, sodium, calcium, magnesium, and potassium in the patient’s blood while removing waste and excess fluid.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Rockwell Medical’s R&D activities focuses on advancing hemodialysis concentrates through the US-based, flexible manufacturing and custom formulation to meet clinic-specific needs. As of December 2024, the company owned rights to four issued US patents, including claims to ferric pyrophosphate citrate ("FPC") in both dialysate and IV compositions, formulations and methods of making, and parenteral nutritional compositions, including Triferic. In FY2024, the company spent US$0.02 million on its R&D activities.